Palliative Sedation for Hematemesis
Sedative Agent Selection
- Midazolam is the preferred sedative for palliative sedation because it has a rapid onset, short half‑life, and can be given intravenously or subcutaneously, allowing flexible dosing. 1
- Continuous infusion should be started at 0.5–1 mg h⁻¹ with rescue boluses of 1–5 mg available for breakthrough symptoms; the infusion can be titrated up to 1–20 mg h⁻¹ to achieve the minimum level of comfort. 1
- Intermittent (bolus‑only) administration is inadequate for maintaining sustained sedation; a continuous infusion is required. 1
Emergency Planning for Catastrophic Hematemesis
- Sedative medications must be prepared in advance together with a clear emergency administration plan for patients at risk of massive hemorrhage. 3
- If the patient is at home and the family cannot administer emergency doses, hospital admission should be considered to ensure rapid access to rescue therapy. 3
- An emergency rescue‑bolus supply should be readily available to manage sudden, severe symptom spikes. 1
Management of Concomitant Opioids
- Opioid analgesics already being used should be continued during sedation unless there are signs of adverse effects such as respiratory depression. 6
- When opioid overdose is suspected, the dose should be reduced gradually rather than stopped abruptly, to avoid withdrawal syndrome. 6
- Midazolam may be co‑administered with morphine or haloperidol when additional symptom control is needed. 1
Continuation and Discontinuation of Other Palliative Medications
- All other palliative symptom‑control drugs should be maintained unless they are ineffective or cause distressing side‑effects. 6
- Medications that do not contribute to the comfort goal should be discontinued to simplify the regimen. 6
Delirium Management
- Antipsychotics are the first‑line agents for delirium; opioids and benzodiazepines can worsen delirium and should be avoided as initial therapy. 7
Alternative Sedative Agents (for Specific Situations)
- Levomepromazine – initial 12.5–25 mg bolus (or 50–75 mg continuous) with effective dosing of 12.5–25 mg every 8 h plus rescue doses; maximum ≈ 300 mg day⁻¹. Provides antipsychotic effect, modest analgesia, and multiple routes of administration. 6
- Chlorpromazine – initial 12.5 mg every 4–12 h IV/IM (or 3–5 mg h⁻¹ IV, or 25–100 mg rectal); effective 37.5–150 mg day⁻¹ parenterally or 75–300 mg day⁻¹ rectally. IV use should be limited to bedridden patients because of a hypotensive risk. 6 (IV warning from Praxis)
- Phenobarbital – bolus 1–3 mg kg⁻¹ SC/IV followed by 0.5 mg kg⁻¹ h⁻¹ infusion; maintenance 50–100 mg h⁻¹. It has no analgesic effect, so concurrent opioid therapy is required. 6
- Propofol – loading dose 20 mg then infusion 50–70 mg h⁻¹. Advantages: very short duration, rapid onset, and easy titration. 6
Routes of Administration
- Allowed routes: intravenous, intramuscular, subcutaneous, rectal, and when appropriate, via stoma or gastrostomy. 1
- Intravenous administration is preferred in active hematemesis to ensure reliable absorption and rapid titration. 2
Hydration and Nutrition Decisions
- Decisions about artificial hydration or nutrition are independent of the sedation decision; they should be evaluated separately. 1
- If artificial hydration/nutrition aggravates the patient’s suffering, reduction or withdrawal should be considered. 6
Family Communication and Support
- Family members should be encouraged to stay with the patient, providing an important opportunity for farewell. 6
- Repeated reassurance that sedation is unlikely to shorten life helps alleviate family anxiety. 6
- Keep families regularly informed about the patient’s condition and what to expect throughout the sedation process. 6
Safety Warnings
- Avoid benzodiazepines in elderly or cognitively impaired patients because of increased risk of further cognitive decline. 2
- Do not initiate benzodiazepines for delirium in patients who have not previously received them. 2
- Lorazepam may cause paradoxical excitation in delirious patients unless therapeutic antipsychotic levels are already present. 2
- Monitor for orthostatic hypotension, especially when neuroleptics are used in the setting of possible hypovolemia from hematemesis. 6